Noemi Esparza, MD; Andrés Purroy, DM, DPhil; Liliana Mesa, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: We read with great interest the review by Steen and colleagues (1) on the outcome of scleroderma renal crisis before and after the availability of angiotensin converting enzyme (ACE) inhibitors. Of the 55 patients in the study who had scleroderma renal crisis, the continuation or acceleration of renal insufficiency in 4 patients raised the question of captopril-related renal toxicity. The authors concluded that Captopril could not have caused renal deterioration in these patients because none of the 4 patients had peripheral blood or urine eosinophilia or improvement of renal failure after withdrawal of captopril.
We wish to
Esparza N, Purroy A, Mesa L. ACE Inhibitors for Scleroderma Renal Crisis. Ann Intern Med. 1991;114:249–250. doi: 10.7326/0003-4819-114-3-249
Download citation file:
Published: Ann Intern Med. 1991;114(3):249-250.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use